Al­ny­lam trail­blaz­er Bar­ry Greene jumps to the helm of a strug­gling Sage Ther­a­peu­tics. Can he de­liv­er an­oth­er come­back?

Sage Ther­a­peu­tics will look to a new chief to lead the way dur­ing its come­back at­tempt.

For­mer Al­ny­lam pres­i­dent Bar­ry Greene — a well known fix­ture in the Boston/Cam­bridge hub — is tak­ing the helm of the neu­ro out­fit, just 6 weeks af­ter the near­by Bio­gen stepped up with a multi­bil­lion-dol­lar bet on the small­er biotech.

Af­ter a 7-year stint as CEO, Jeff Jonas will step in­to a new role now as chief in­no­va­tion of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER